Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal The Wall Street Journal Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. Barron’s Novartis to buy Tourmaline Bio, gaining promising heart medicine statnews.com Novartis spends $1.4B for Tourmaline and cardiovascular med that impressed …
Read More »Tag Archives: Tourmaline
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising targeted therapy with the potential to reduce systemic inflammation—an independent and significant driver of cardiovascular risk—addressing a critical unmet need in ASCVD treatment Offer price of USD 48 per share valuing the company at approximately …
Read More »